August 2022

Upadacitinib pour le traitement de la spondylarthrite axiale active non radiographique (SELECT-AXIS 2) : Essai de phase 3 randomisé, en double aveugle, contrôlé par placebo

Lancet 2022 doi: 10.1016/S0140-6736(22)01212-0

Upadacitinib significantly improved the signs and symptoms of nr-axSpA compared with placebo at Week 14 in this investigation. Prior to this, upadacitinib had been shown to be effective in patients with AS. This study aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.

Keywords:

April 2022

Évaluation de la réponse à la vaccination anti-pneumococcique conjuguée 13-valent chez les patients atteints de polyarthrite rhumatoïde recevant de l'upadacitinib : résultats d'une étude d'extension ouverte de phase 2

RMD Open. 2022;8(1):e002110 doi: 10.1136/rmdopen-2021-002110

Vaccine sub-study of the BALANCE-EXTEND upadacitinib trial finds that approximately two-thirds of patients receiving upadacitinib 15 mg once-daily achieve a satisfactory humoral response to pneumococcal 13-valent conjugate (PCV-13) vaccine, despite receiving concomitant methotrexate (MTX).It is well known that a weakened immune response, comorbidities and immunosuppressant drug therapy all contribute to an increased susceptibility to infections in patients with RA. Likewise, the morbidity and mo...

Keywords:

March 2022

Innocuité et efficacité à long terme de l'upadacitinib ou de l'adalimumab chez les patients atteints de polyarthrite rhumatoïde : résultats à 3 ans de l'étude SELECT-COMPARE

RMD Open. 2022;8(1):e002012 doi: 10.1136/rmdopen-2021-002012

Upadacitinib continues to show consistently better clinical responses, compared with adalimumab, through 3 years, including rates of remission and low disease activity, physical function and pain severity.Following the favourable upadacitinib efficacy data seen in the SELECT-COMPARE study at 72 weeks, Fleischmann, et al. assessed the long-term safety and efficacy of upadacitinib versus adalimumab over 3 years in the long-term extension of this study, with promising results. ...

Keywords:

January 2022

Inhibition de la progression des lésions articulaires structurelles avec l'upadacitinib dans la polyarthrite rhumatoïde : résultats à un an du programme de phase 3 SELECT

Rheumatology (Oxford). 2021. Epub ahead of print. doi: 10.1093/rheumatology/keab861

.

Keywords: